Chief Business Officer at evitria
evitria Europe
London, Great Britain
Mail: ds@evitria.com
As Chief Business Officer, Desmond Schofield leads strategic initiatives focused on fostering growth and innovation. His responsibilities include crafting and implementing strategies to enhance customer service and satisfaction within a constantly evolving market.
With a Doctorate in biochemical engineering from the University College London, Desmond Schofield has gained invaluable experience in numerous fields across the biotechnology sector and beyond: he is a professional in business development and new technology ventures; furthermore, Desmond Schofield is experienced in synthetic biology as well as in bioprocessing and immuno-oncology. This and more sums up to a broad portfolio of profound expert knowledge that Desmond Schofield brings to evitria.
LinkedIn profile: Desmond Schofield
Articles
Delivering material with the same quality at every scale, and with several years in between campaigns, enabled our client to rapidly move through development stages without having to undertake difficult troubleshooting activities or worry about their material quality.
The design of your antibody sequence is the single most important step in your therapeutic development journey. Weak binding, off-target effects, and insufficient activity can all improve via sequence engineering.
Afucosylated antibodies are promising tools in the fight against several diseases. But how are they developed? That is what we are going to find out in this article.
Publications
Bacterial cells as engineered chassis. In Synthetic Biology Handbook, ed. D.N. Nesbeth
Boca Raton: Taylor & Francis 01. Jan. 2016
Detecting cell lysis using viscosity monitoring in E. coli fermentation to prevent product loss
Biotechnology Progress 8;32(4):1069-76 25. Apr. 2016
Boca Raton: Taylor & Francis 01. Jan. 2016
Biotechnology Progress, 8;32(4):840-7 06. May. 2016